Tempest Therapeutics, Inc. (TPST)

USD 0.7

(-11.57%)

Market Cap (In USD)

30.48 Million

Revenue (In USD)

-

Net Income (In USD)

-29.49 Million

Avg. Volume

2.39 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.6986-6.0
PE
-
EPS
-
Beta Value
-2.776
ISIN
US87978U1088
CUSIP
87978U108
CIK
1544227
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen R. Brady J.D., LLM
Employee Count
-
Website
https://www.tempesttx.com
Ipo Date
2012-11-12
Details
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.